PSMAfore: Lutetium-177–PSMA-617 in Metastatic CRPC

News
Video

Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Related Videos
Related Content